# Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC

> **NCT04911959** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 50 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Lenvatinib

## Interventions

- **DRUG:** Lenvatinib
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT04911959
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04911959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04911959, "Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04911959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*